However, their increased efficacy in vivo was also found to be dependent upon secondary overexpression of CXCR3, the main receptor for the IFNγ-dependent chemokine ligands CXCL-9 and CXCL-10 found at elevated levels the TME of inflamed tumours [208]. This evidence concerns the gene CXCL9 and neoplasm.